COMMUNIQUÉS West-GlobeNewswire

FDA Grants Pediatric Disease Designation for Mateon’s OT101
23/09/2019
For treatment of diffuse intrinsic pontine glioma (DIPG), a difficult to treat form of childhood brain tumor AGOURA HILLS, Calif., Sept. 23, 2019 (GLOBE NEWSWIRE) -- Mateon Therapeutics Inc. (OTCQB:MATN) announced today [...]
Medtronic Announces FDA Approval and U.S. Launch of Next-Generation Evolut™ PRO+ TAVR System for Treatment of Symptomatic Severe Aortic Stenosis Patients
23/09/2019
Improved Functionality Across Four Valve Sizes and Lowest Delivery Profile on the Market, the Evolut PRO+ TAVR System Launches in U.S. as TAVR Patient Population Grows DUBLIN, Sept. 23, 2019 (GLOBE NEWSWIRE) -- [...]
Konica Minolta Healthcare CEO David Widmann to Share Insights on Creating Successful Strategic Partnerships at Health Connect South 2019 Annual Meeting
23/09/2019
WAYNE, N.J., Sept. 23, 2019 (GLOBE NEWSWIRE) -- Health Connect South, the premier platform for regional health collaboration in the Southeast, will host David Widmann, President & CEO of Konica Minolta Healthcare [...]
Flexion Therapeutics Sponsors a Memorial to the Victims of the Opioid Crisis to Raise Awareness of the Tragic Consequences of the Opioid Epidemic Across the U.S.
23/09/2019
Interactive memorial developed by the National Safety Council pays tribute to more than 22,000 victims of the opioid crisis and offers resources to help stem the epidemic Exhibit will be on display Sept. 23-28 at the [...]
Onconova Therapeutics, Inc. Announces $3.4 Million Registered Direct Offering of Common Stock
23/09/2019
NEWTOWN, Pa., Sept. 23, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (Nasdaq: ONTX) , a Phase 3 stage biopharmaceutical company discovering and developing novel products to treat cancer, with a focus on [...]
Transactions under Novozymes’ stock buyback program
23/09/2019
Please read the full announcement in the attached PDF Attachment 2019_37_Stock_Buybackprogram_EN
Abeona Therapeutics Provides Regulatory Update Ahead of Pivotal Phase 3 Clinical Trial for EB-101 in Recessive Dystrophic Epidermolysis Bullosa
23/09/2019
Company to provide additional transport stability data points in response to FDA Clinical Hold Letter CMC clearance for VIITAL™ trial anticipated in Q4 2019 Investor conference call today, Monday, September 23 at 09:30 [...]
Cannabix Technologies Expands Marijuana Breathalyzer Portfolio with Licensing of UBC Technology for Workplace and Parental Use
23/09/2019
Cannabix and UBC are working together to develop marijuana breathalyzer technology for a range of markets VANCOUVER, British Columbia, Sept. 23, 2019 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: [...]
Resverlogix Announces BETonMACE Trial Results Accepted for Presentation at American Heart Association’s Scientific Sessions 2019
23/09/2019
Confirms BETonMACE database lock; reaffirms September 30, 2019 topline data availability CALGARY, Alberta, Sept. 23, 2019 (GLOBE NEWSWIRE) -- Resverlogix Corp. (“Resverlogix” or the "Company") (TSX:RVX) announced today [...]
Pascal Biosciences Discovers Cannabinoids Activate the Major Histocompatibility Complex to Aid Cancer Treatment
23/09/2019
VANCOUVER, British Columbia, and SEATTLE, Sept. 23, 2019 (GLOBE NEWSWIRE) -- Pascal Biosciences Inc. ( TSX.V:PAS ) (“Pascal” or the “Company”) today revealed the mechanism whereby cannabinoids may directly aid in cancer [...]
Mustang Bio Announces Phase 1 Clinical Trial Evaluating MB-105 for Prostate Stem Cell Antigen-Positive Castration-Resistant Prostate Cancer Enrolling Patients at City of Hope
23/09/2019
NEW YORK, Sept. 23, 2019 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into [...]
resTORbio to Present Findings on Investigational TORC1 Inhibitor RTB101 in Late-Breaking Session at IDWeek™ 2019
23/09/2019
BOSTON, Sept. 23, 2019 (GLOBE NEWSWIRE) -- resTORbio, Inc., (Nasdaq: TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or treat aging-related [...]
Auransa Presents New Preclinical Data on AU-409, a Novel, AI-Derived Drug Candidate for the Treatment of Hepatocellular Carcinoma
23/09/2019
Oral Presentation at the 13th Annual Conference of the International Liver Cancer Association Highlights Promising Antitumor Activity in Preclinical Cancer Model and HCC Cell Lines PALO ALTO, Calif., Sept. 23, 2019 ( [...]
Novo Nordisk A/S – Share repurchase programme
23/09/2019
Novo Nordisk A/S – Share repurchase programme Bagsværd, Denmark, 23 September 2019 – On 9 August 2019, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the [...]
BeyondSpring’s Plinabulin Continues to Build on Superior Product Profile in Breast Cancer Trial for Neutropenia Prevention
23/09/2019
Data to be Presented at ESMO Congress 2019 in Barcelona NEW YORK, Sept. 23, 2019 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer [...]
Passage Bio Grows Management Team with Chief Medical Officer and General Counsel Appointments
23/09/2019
Gary Romano, M.D., Ph.D joins as chief medical officer from Janssen R&D and Edgar (Chip) Cale, J.D., joins as general counsel from GlaxoSmithKline PHILADELPHIA, Sept. 23, 2019 (GLOBE NEWSWIRE) -- Passage Bio, a [...]
Spring Bank to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference in New York, NY
23/09/2019
HOPKINTON, Mass., Sept. 23, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, [...]
ORYZON Updates on New Activities
23/09/2019
To present at upcoming international conference - ESMO-2019 in Barcelona, Spain - 19th Annual Biotech in Europe Investment Forum in Basel, Switzerland - 4th Annual MarketsandMarkets Epigenetics Congress in London, UK - [...]
Entera Bio Reports Positive Results from a Phase 2 PK/PD Study of Oral PTH (1-34) in Patients with Hypoparathyroidism
23/09/2019
Results of a Phase 2 PK/PD study of Oral PTH (1-34) in patients with hypoparathyroidism were presented at the American Society for Bone and Mineral Research Annual Meeting Data suggest favorable pharmacologic and [...]

Pages